30岁以下患者主动脉瓣与主动脉根部置换假体选择
该单中心回顾性研究纳入1998至2016年99例16-30岁行主动脉瓣/根部置换患者,比较机械瓣与生物瓣的远期结局。中远期随访显示瓣膜类型不影响再次手术率或生存率,而置换瓣膜尺寸≤21 mm是再次手术和跨瓣压差进展的显著危险因素。
要点
- 年轻患者机械瓣与生物瓣的再次手术率和生存率无显著差异。
- 置换瓣膜尺寸≤21 mm是再次手术的显著危险因素。
- 小尺寸瓣膜与随访期间平均跨瓣压差进展相关。
核心结论
- 在中远期随访中,机械瓣与生物瓣/生物假体瓣的选择不影响该年轻队列的再次手术率或生存率。
- 较小的主动脉瓣置换尺寸(≤21 mm)是再次手术和平均主动脉瓣跨瓣压差进展的显著危险因素。
研究设计与样本
- 单中心回顾性研究,1998至2016年纳入99例16-30岁患者。
- 手术方式包括主动脉瓣置换57例、主动脉瓣置换+冠状动脉上升主动脉置换6例、主动脉根部置换36例。
- 前瞻性维护的主动脉瓣数据库被回顾性审查以完成纵向功能和临床数据,总随访493患者年。
主要发现
- 手术指征包括原发性狭窄/关闭不全52%(n=51)、马方综合征10%(n=10)、心内膜炎33.3%(n=33)。
- 30天/院内死亡率和卒中率分别为3.0%(n=3)和1%(n=1)。
- 机械瓣组1、5、10年免于主动脉瓣再次手术率分别为89.1%、84.6%、69.4%,生物瓣/生物假体瓣组分别为89.6%、70.9%、57.6%(log rank P = .279)。
关键数值与推荐
- 置换瓣膜尺寸≤21 mm是再次手术的显著危险因素,并与随访期间平均主动脉瓣跨瓣压差进展相关。
- 瓣膜类型对再次手术或生存率无影响。
临床怎么用
- 对于30岁及以下行主动脉瓣/根部置换的患者,机械瓣与生物瓣选择可不作为影响再次手术或生存的主要决策因素。
- 应尽量避免使用≤21 mm的小尺寸瓣膜,以降低再次手术风险和跨瓣压差进展。
局限性
- 单中心回顾性研究,样本量99例,可能存在选择偏倚。
- 总随访493患者年,中远期随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Long-term outcomes of prosthetic aortic valve/root replacement in patients aged 30 years or younger are not well understood. We report our single institutional experience in this young cohort. METHODS: From 1998 to 2016, 99 patients (age range, 16-30 years) underwent aortic valve replacement (n = 57), aortic valve replacement and supracoronary ascending aorta replacement (n = 6), or aortic root replacement (n = 36). A prospectively maintained aortic valve database was retrospectively reviewed to complete longitudinal functional and clinical data. Total follow-up was 493 patient years. RESULTS: Surgical indications included primary stenosis/insufficiency (52% [n = 51]), Marfan syndrome (10% [n = 10]), and endocarditis (33.3% [n = 33]). Fifty-eight patients (59%) underwent mechanical valve replacement, with 41 patients (41%) receiving a biologic/bioprosthetic valve. Twenty-five patients underwent aortic valve reoperation after index procedure with following indications: prosthesis-patient mismatch 1.0% (n = 1), prosthetic valve degeneration/dysfunction 10% (n = 10), connective tissue 2% (n = 2), and endocarditis 12% (n = 12). Mortality (30-day/in-hospital) and stroke rate were 3.0% (n = 3) and 1% (n = 1), respectively. One-, 5-, and 10-year actuarial freedom from aortic valve reoperation by valve type was 89.1%, 84.6%, and 69.4% for the Mechanical Valve group and 89.6%, 70.9%, and 57.6% for the Biologic/Bioprosthetic Valve group, respectively (log rank P = .279). Replacement valve size ≤21 mm was a significant risk factor for reoperation, and was associated with progression of mean aortic valve transvalvular gradients over follow-up. Valve type had no effect. CONCLUSIONS: The choice of mechanical versus biologic/bioprosthetic valve does not affect freedom from reoperation or survival rates in this young cohort during mid- to long-term follow-up. Smaller aortic valve replacement size (≤21 mm) is a significant risk factor for reoperation and progression of mean aortic valve gradients.
引用
- Milewski RK, Habertheuer A, Bavaria JE, et al. Selection of prosthetic aortic valve and root replacement in patients younger than age 30 years. J Thorac Cardiovasc Surg. 2018. PMID: 30669231. doi:10.1016/j.jtcvs.2018.06.102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。